ArticleInternational journal of hematology2025

Phase 1 study of talquetamab, a humanized GPRC5D x CD3 bispecific antibody, in Japanese patients with relapsed/refractory MM.

Shinsuke Iida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.